116 related articles for article (PubMed ID: 37096786)
21. Incidence and Risk of Second Primary Malignant Neoplasm After a First Head and Neck Squamous Cell Carcinoma.
Adjei Boakye E; Buchanan P; Hinyard L; Osazuwa-Peters N; Schootman M; Piccirillo JF
JAMA Otolaryngol Head Neck Surg; 2018 Aug; 144(8):727-737. PubMed ID: 30027284
[TBL] [Abstract][Full Text] [Related]
22. Refusal of Cancer-Directed Surgery in Head and Neck Squamous Cell Carcinoma Patients.
Crippen MM; Elias ML; Weisberger JS; Brady JS; Eloy JA; Baredes S; Park RCW
Laryngoscope; 2019 Jun; 129(6):1368-1373. PubMed ID: 30070700
[TBL] [Abstract][Full Text] [Related]
23. Is There an Association Between Insurance Status and Survival and Treatment of Primary Bone and Extremity Soft-tissue Sarcomas? A SEER Database Study.
Smartt AA; Jang ES; Tyler WK
Clin Orthop Relat Res; 2020 Mar; 478(3):527-536. PubMed ID: 31390340
[TBL] [Abstract][Full Text] [Related]
24. Definitive radiation with concurrent cetuximab vs. radiation with or without concurrent cytotoxic chemotherapy in older patients with squamous cell carcinoma of the head and neck: Analysis of the SEER-medicare linked database.
Zandberg DP; Cullen K; Bentzen SM; Goloubeva OG
Oral Oncol; 2018 Nov; 86():132-140. PubMed ID: 30409293
[TBL] [Abstract][Full Text] [Related]
25. Adherence to National Comprehensive Cancer Network guidelines for time to initiation of postoperative radiation therapy for patients with head and neck cancer.
Graboyes EM; Garrett-Mayer E; Sharma AK; Lentsch EJ; Day TA
Cancer; 2017 Jul; 123(14):2651-2660. PubMed ID: 28241092
[TBL] [Abstract][Full Text] [Related]
26. The effect of insurance status on treatment modality in advanced oral cavity cancer.
Sivarajah S; Ghods-Esfahani D; Quimby A; Makki F; Montagna G; Seikaly H
J Otolaryngol Head Neck Surg; 2023 Apr; 52(1):26. PubMed ID: 37072807
[TBL] [Abstract][Full Text] [Related]
27. Racial/Ethnic disparities in socioeconomic status, diagnosis, treatment and survival among medicare-insured men and women with head and neck cancer.
Du XL; Liu CC
J Health Care Poor Underserved; 2010 Aug; 21(3):913-30. PubMed ID: 20693735
[TBL] [Abstract][Full Text] [Related]
28. Predictors of IMRT and conformal radiotherapy use in head and neck squamous cell carcinoma: a SEER-Medicare analysis.
Sher DJ; Neville BA; Chen AB; Schrag D
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e197-206. PubMed ID: 21596483
[TBL] [Abstract][Full Text] [Related]
29. Type II diabetes and metabolic syndrome in relation to head and neck squamous cell carcinoma risk: a SEER-Medicare database study.
Stott-Miller M; Chen C; Schwartz SM
Cancer Epidemiol; 2013 Aug; 37(4):428-33. PubMed ID: 23562170
[TBL] [Abstract][Full Text] [Related]
30. Comparison of efficacy and toxicity of chemoradiation regimens for head and neck squamous cell carcinoma primary treatment.
McCusker MG; Mehra R; Amr S; Taylor RJ; Cullen KJ; Goloubeva OG
Head Neck; 2022 Mar; 44(3):749-759. PubMed ID: 34931731
[TBL] [Abstract][Full Text] [Related]
31. The impact of the multidisciplinary tumor board on head and neck cancer outcomes.
Liu JC; Kaplon A; Blackman E; Miyamoto C; Savior D; Ragin C
Laryngoscope; 2020 Apr; 130(4):946-950. PubMed ID: 31095740
[TBL] [Abstract][Full Text] [Related]
32. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis.
Halpern MT; Ward EM; Pavluck AL; Schrag NM; Bian J; Chen AY
Lancet Oncol; 2008 Mar; 9(3):222-31. PubMed ID: 18282806
[TBL] [Abstract][Full Text] [Related]
33. Comorbidity and early diagnosis of head and neck cancer in a Medicare population.
Reid BC; Warren JL; Rozier G
Am J Prev Med; 2004 Dec; 27(5):373-8. PubMed ID: 15556736
[TBL] [Abstract][Full Text] [Related]
34. Head and neck squamous cell cancers in the United States are rare and the risk now is higher among white individuals compared with black individuals.
Fakhry C; Krapcho M; Eisele DW; D'Souza G
Cancer; 2018 May; 124(10):2125-2133. PubMed ID: 29533459
[TBL] [Abstract][Full Text] [Related]
35. A novel nomogram and risk classification system for predicting overall survival in head and neck squamous cell cancer with distant metastasis at initial diagnosis.
Zhu RQ; Zhang YM; Luo XY; Shen WY; Zhu HY
Eur Arch Otorhinolaryngol; 2023 Mar; 280(3):1467-1478. PubMed ID: 36316576
[TBL] [Abstract][Full Text] [Related]
36. Impact of the insurance type of head and neck cancer patients on their hospitalization utilization patterns.
Gupta A; Sonis ST; Schneider EB; Villa A
Cancer; 2018 Feb; 124(4):760-768. PubMed ID: 29112234
[TBL] [Abstract][Full Text] [Related]
37. Rigid Esophagoscopy for Head and Neck Cancer Staging and the Incidence of Synchronous Esophageal Malignant Neoplasms.
McGarey PO; O'Rourke AK; Owen SR; Shonka DC; Reibel JF; Levine PA; Jameson MJ
JAMA Otolaryngol Head Neck Surg; 2016 Jan; 142(1):40-5. PubMed ID: 26633039
[TBL] [Abstract][Full Text] [Related]
38. Nomograms predicting long-term overall survival and cancer-specific survival in head and neck squamous cell carcinoma patients.
Ju J; Wang J; Ma C; Li Y; Zhao Z; Gao T; Ni Q; Sun M
Oncotarget; 2016 Aug; 7(32):51059-51068. PubMed ID: 27419636
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of HPV-Associated Squamous Cell Carcinoma of the Head and Neck: Impact of Race and Socioeconomic Status.
Pike LRG; Royce TJ; Mahal AR; Kim DW; Hwang WL; Mahal BA; Sanford NN
J Natl Compr Canc Netw; 2020 Feb; 18(2):177-184. PubMed ID: 32023531
[TBL] [Abstract][Full Text] [Related]
40. Treatment modalities, adverse events, and survival outcomes in older patients with head and neck squamous cell carcinoma.
Amr S; Ioffe D; Suzuki I; Mehra R; Cullen K; Goloubeva O
Head Neck; 2021 Dec; 43(12):3935-3945. PubMed ID: 34632677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
